Thymidine kinase and cancer monitoring

Cancer Letters

Volumn 316, Issue 1, 2012, Pages 6-10

  Aufderklamm, Stefan ^a   Todenhöfer, Tilman ^a   Gakis, Georgios ^a   Kruck, Stephan ^a   Hennenlotter, Joerg ^a   Stenzl, Arnulf ^a   Schwentner, Christian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cancer monitoring; Cell proliferation; Thymidine kinase 1

Indexed keywords

ENZYME ANTIBODY; THYMIDINE KINASE; THYMIDINE KINASE 1; THYMIDINE KINASE 2; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; DIGESTIVE SYSTEM CANCER; DNA SYNTHESIS; ENZYME ACTIVITY; HUMAN; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY;

EID: 84855347011     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.025     Document Type: Review

References (36)

1. Munch-Petersen B. Enzymatic regulation of cytosolic thymidine kinase 1 and mitochondrial thymidine kinase 2: a mini review. Nucleos Nucleot Nucl Acids 2010, 29(4-6):363-369.
2. Johansson K., et al. Structural basis for substrate specificities of cellular deoxyribonucleoside kinases. Nat Struct Biol 2001, 8(7):616-620.
3. Welin M., et al. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci USA 2004, 101(52):17970-17975.
4. Sandrini M.P., Piskur J. Deoxyribonucleoside kinases: two enzyme families catalyze the same reaction. Trends Biochem Sci 2005, 30(5):225-228.
5. Littlefield J.W. The use of drug-resistant markers to study the hybridization of mouse fibroblasts. Exp Cell Res 1966, 41(1):190-196.
6. Chabes A., Thelander L. DNA building blocks at the foundation of better survival. Cell Cycle 2003, 2(3):171-173.
7. Dou Q.P., Pardee A.B. Transcriptional activation of thymidine kinase, a marker for cell cycle control. Prog Nucleic Acid Res Mol Biol 1996, 53:197-217.
8. Munch-Petersen B., Tyrsted G., Cloos L. Reversible ATP-dependent transition between two forms of human cytosolic thymidine kinase with different enzymatic properties. J Biol Chem 1993, 268(21):15621-15625.
9. Munch-Petersen B. Reversible tetramerization of human TK1 to the high catalytic efficient form is induced by pyrophosphate, in addition to tripolyphosphates, or high enzyme concentration. FEBS J 2009, 276(2):571-580.
10. Ke P.Y., Chang Z.F. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 2004, 24(2):514-526.
11. Wang N., et al. Investigation on cell proliferation with a new antibody against thymidine kinase 1. Anal Cell Pathol 2001, 23(1):11-19.
12. He Q., et al. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. Int J Biol Markers 2000, 15(2):139-146.
13. Wu J., et al. A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res 2000, 20(6C):4815-4820.
14. Mao Y., et al. A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest 2002, 20(7-8):922-931.
15. Zou L., et al. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers 2002, 17(2):135-140.
16. Wu C., et al. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 2003, 277(1-2):157-169.
17. Wang L., Eriksson S. Cloning and characterization of full-length mouse thymidine kinase 2: the N-terminal sequence directs import of the precursor protein into mitochondria. Biochem J 2000, 351 Pt 2:469-476.
18. Wang L., Saada A., Eriksson S. Kinetic properties of mutant human thymidine kinase 2 suggest a mechanism for mitochondrial DNA depletion myopathy. J Biol Chem 2003, 278(9):6963-6968.
19. Perez-Perez M.J., et al. Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future. Med Res Rev 2008, 28(5):797-820.
20. Chen Z., et al. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Anticancer Res 2008, 28(6B):3897-3907.
21. Huang S., et al. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Asian Pac J Cancer Prev 2011, 12(2):497-505.
22. Li Z., et al. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma. Anticancer Res 2010, 30(4):1295-1299.
23. Mao Y., et al. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. Oncol Rep 2005, 13(5):837-846.
24. He Q., et al. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 2004, 25(4):945-953.
25. He Q., et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res 2006, 26(6C):4753-4759.
26. Chen Y., et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1247 cancer patients in routine clinical settings. Int J Clin Oncol 2010, 15(4):359-368.
27. Yusa T., et al. Activity of the cytosolic isozyme of thymidine kinase in human primary lung tumors with reference to malignancy. Cancer Res 1988, 48(17):5001-5006.
28. Li H.X., et al. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol Rep 2005, 13(1):145-149.
29. Holdenrieder S., et al. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer. Anticancer Res 2010, 30(5):1855-1862.
30. Mizutani Y., et al. The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma. Cancer 2003, 98(4):730-736.
31. Nisman B., et al. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology 2010, 76(2):513e1-6.
32. Kruck S., et al. Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications. BJU Int 2011.
33. Gakis G., et al. XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma. World J Urol 2010.
34. Zhang J., et al. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 2006, 15(2):455-461.
35. Pan Z.L., et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol 2010, 136(8):1193-1199.
36. Li Z., et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas. Eur J Cancer Prev 2010, 19(4):313-318.